Background Multiple sclerosis (MS) is the most common cause of neurological disability in
young adults worldwide and approximately half of those affected are in Europe. The …

Objective: The chemotherapeutic agent mitoxantrone was approved for use in multiple
sclerosis (MS) in 2000. After a review of all the available evidence, the original report of the …

Background Psychiatric comorbidity is prevalent in persons with multiple sclerosis (MS). Few
studies have assessed whether second-generation disease-modifying therapies (DMT) are …

Background On the basis of encouraging preliminary results, we conducted a randomized,
controlled trial to determine whether minocycline reduces the risk of conversion from a first …

Objective We aimed to evaluate the validity and reliability of multiple screening measures
for depression and anxiety for use in the clinical care of people with multiple sclerosis (MS). …

Objective To determine whether anxiety and depression are associated with cognition in
multiple sclerosis (MS), and whether these associations are similar in other immune-mediated …

Objective Vascular comorbidities are associated with reduced cognitive performance and
with changes in brain structure in people with multiple sclerosis (MS). Understanding causal …

Background One-off serum levels of neurofilament light chain (sNfL) is an established
predictor of emerging disease activity in multiple sclerosis (MS). However, the importance of …

Background: Immune-mediated inflammatory diseases (IMID), such as inflammatory bowel
disease (IBD), multiple sclerosis (MS), and rheumatoid arthritis (RA), are highly prevalent in …

Objective To determine whether comorbid diabetes and hypertension are associated with
cognition in multiple sclerosis (MS) after accounting for psychiatric comorbidities. Methods …